Patient characteristics and AD-CD154-CLL dose
| Patient . | Age/gender . | Rai stage/risk . | Prior chemotherapy . | Pretreatment lymphocyte count* . | Group . | Viable cells administered . |
|---|---|---|---|---|---|---|
| 001 | 69/male | II/intermediate | No | 92 | Pilot | 3.0 × 108 |
| 002 | 64/male | II/intermediate | Yes | 310 | Pilot | 3.4 × 108 |
| 003 | 57/male | II/intermediate | No | 61 | 1 | 3.6 × 108 |
| 004 | 59/female | II/intermediate | No | 22 | 1 | 3.0 × 108 |
| 005 | 60/male | II/intermediate | Yes | 22 | 1 | 3.2 × 108 |
| 006 | 75/male | II/intermediate | No | 27 | 2 | 8.1 × 108 |
| 007 | 79/female | III/high | No | 222 | 2 | 9.2 × 108 |
| 008 | 67/male | IV/high | Yes | 387 | 2 | 7.0 × 108 |
| 009 | 55/male | II/intermediate | No | 68 | 3 | 2.7 × 109 |
| 010 | 37/male | II/intermediate | Yes | 301 | 3 | 3.0 × 109 |
| 011 | 71/male | IV/high | No | 198 | 3 | 2.6 × 109 |
| Patient . | Age/gender . | Rai stage/risk . | Prior chemotherapy . | Pretreatment lymphocyte count* . | Group . | Viable cells administered . |
|---|---|---|---|---|---|---|
| 001 | 69/male | II/intermediate | No | 92 | Pilot | 3.0 × 108 |
| 002 | 64/male | II/intermediate | Yes | 310 | Pilot | 3.4 × 108 |
| 003 | 57/male | II/intermediate | No | 61 | 1 | 3.6 × 108 |
| 004 | 59/female | II/intermediate | No | 22 | 1 | 3.0 × 108 |
| 005 | 60/male | II/intermediate | Yes | 22 | 1 | 3.2 × 108 |
| 006 | 75/male | II/intermediate | No | 27 | 2 | 8.1 × 108 |
| 007 | 79/female | III/high | No | 222 | 2 | 9.2 × 108 |
| 008 | 67/male | IV/high | Yes | 387 | 2 | 7.0 × 108 |
| 009 | 55/male | II/intermediate | No | 68 | 3 | 2.7 × 109 |
| 010 | 37/male | II/intermediate | Yes | 301 | 3 | 3.0 × 109 |
| 011 | 71/male | IV/high | No | 198 | 3 | 2.6 × 109 |
Lymphocyte count × 10−3/mm3 of blood prior to leukapheresis.